Latest & greatest articles for enalapril

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on enalapril or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on enalapril and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for enalapril

1. Protective role of enalapril in chemotherapy-induced cardiotoxicity: grading the evidence through systematic review and meta-analysis

Protective role of enalapril in chemotherapy-induced cardiotoxicity: grading the evidence through systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

2. Enalapril

Enalapril Top results for enalapril - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for enalapril The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. (Full text)

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. Consensus guidelines recommend the use of mineralocorticoid receptor antagonists (MRAs) for selected patients with symptomatic heart failure and reduced ejection fraction (HFrEF) to reduce morbidity and mortality; however, the use of MRAs in combination with other inhibitors of the renin (...) % or less to treatment with enalapril 10 mg twice daily or sacubitril/valsartan 97/103 mg twice daily (previously known as LCZ696 [200 mg twice daily]) in addition to guideline-directed medical therapy. Use of MRAs was encouraged but left to the discretion of study investigators. Serum potassium level was measured at every study visit. The incidence of hyperkalemia (potassium level >5.5 mEq/L) and severe hyperkalemia (potassium level >6.0 mEq/L) among patients treated or not treated with an MRA

2016 JAMA cardiology PubMed

4. Aliskiren, Enalapril, or Both in Heart Failure. (PubMed)

Aliskiren, Enalapril, or Both in Heart Failure. 27532843 2016 08 18 2018 12 02 1533-4406 375 7 2016 08 18 The New England journal of medicine N. Engl. J. Med. Aliskiren, Enalapril, or Both in Heart Failure. 702 10.1056/NEJMc1606625 McMurray John J V JJ Dickstein Kenneth K Køber Lars V LV eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Amides 0 Angiotensin-Converting Enzyme Inhibitors 0 Fumarates 69PN84IO1A Enalapril EC 3.4.23.15 Renin AIM IM N Engl J Med. 2016 Apr 21;374(16 (...) ):1521-32 27043774 N Engl J Med. 2016 Aug 18;375(7):701-2 27532844 Amides therapeutic use Angiotensin-Converting Enzyme Inhibitors therapeutic use Enalapril therapeutic use Female Fumarates therapeutic use Heart Failure drug therapy Humans Male Renin antagonists & inhibitors 2016 8 18 6 0 2016 8 18 6 0 2016 8 19 6 0 ppublish 27532843 10.1056/NEJMc1606625 10.1056/NEJMc1606625#SA2

2016 NEJM

5. Aliskiren, Enalapril, or Both in Heart Failure. (Full text)

Aliskiren, Enalapril, or Both in Heart Failure. 27532844 2016 08 18 2018 12 02 1533-4406 375 7 2016 08 18 The New England journal of medicine N. Engl. J. Med. Aliskiren, Enalapril, or Both in Heart Failure. 701-2 10.1056/NEJMc1606625 Silva Alessandra R AR University of Brasilia, Brasilia, Brazil nevesfar@gmail.com. Martini Alexandre A University of Brasilia, Brasilia, Brazil nevesfar@gmail.com. Neves Francisco A R FA University of Brasilia, Brasilia, Brazil nevesfar@gmail.com. eng Letter (...) Comment United States N Engl J Med 0255562 0028-4793 0 Amides 0 Angiotensin-Converting Enzyme Inhibitors 0 Fumarates 69PN84IO1A Enalapril EC 3.4.23.15 Renin AIM IM N Engl J Med. 2016 Apr 21;374(16):1521-32 27043774 N Engl J Med. 2016 Aug 18;375(7):702 27532843 Amides therapeutic use Angiotensin-Converting Enzyme Inhibitors therapeutic use Enalapril therapeutic use Female Fumarates therapeutic use Heart Failure drug therapy Humans Male Renin antagonists & inhibitors 2016 8 18 6 0 2016 8 18 6 0 2016 8

2016 NEJM PubMed

6. Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. (Full text)

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. Among patients with chronic heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown. We compared the ACE inhibitor enalapril with the renin inhibitor aliskiren (to test superiority or at least noninferiority) and with the combination of the two treatments (to test superiority) in patients with heart failure and a reduced (...) ejection fraction.After a single-blind run-in period, we assigned patients, in a double-blind fashion, to one of three groups: 2336 patients were assigned to receive enalapril at a dose of 5 or 10 mg twice daily, 2340 to receive aliskiren at a dose of 300 mg once daily, and 2340 to receive both treatments (combination therapy). The primary composite outcome was death from cardiovascular causes or hospitalization for heart failure.After a median follow-up of 36.6 months, the primary outcome occurred

2016 NEJM PubMed

7. PARADIGM?HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in Heart Failure

PARADIGM?HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in Heart Failure RXFILES PRELIMINARY TRIAL SUMMARY LYNETTE KOSAR JAN 7 TH , 2015 – WWW.RXFILES.CA Page 1 of 3 PARADIGM-HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in HF 1 Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality & morbidity in HF BOTTOM LINE ? In PARADIGM-HF, clinically stable patients with heart failure (HF) (NYHA class I 5%, class (...) 2 (±5.5kg/m 2 ), SCr 99.9µmol/L (or SCr 1.13mg/dL ±0.3) ? Mean LVEF 29.5% (±6.2%), ischemic cardiomyopathy ~60%, median BNP 253pg/mL (IQR 153-474) ? Median NT-proBNP: LCZ696 1631pg/mL (IQR 885-3154) versus enalapril 1594pg/mL (IQR 886-3305) ? NYHA: class I ~5%, class II ~70.5%, III ~24%, IV ~0.7%. Note: classification at randomization exclusion of class I was applied at screening. ? HTN 70.5%, DM ~35%, AF ~37%, hospitalized for HF ~63%, MI ~43%, stroke ~8.5% ? Treatment at randomization: ACEI

2016 RxFiles

8. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients (Full text)

Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients The angiotensin-receptor-neprilysin inhibitor (ARNI) LCZ696 reduced cardiovascular deaths and all-cause mortality compared with enalapril in patients with chronic heart failure in the prospective comparison of ARNI with an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. To more (...) cardiovascular (80.9%), and the risk of cardiovascular death was significantly reduced by treatment with LCZ (hazard ratio, HR 0.80, 95% CI 0.72-0.89, P < 0.001). Among cardiovascular deaths, both sudden cardiac death (HR 0.80, 95% CI 0.68-0.94, P = 0.008) and death due to worsening heart failure (HR 0.79, 95% CI 0.64-0.98, P = 0.034) were reduced by treatment with LCZ696 compared with enalapril. Deaths attributed to other cardiovascular causes, including myocardial infarction and stroke, were infrequent

2015 EvidenceUpdates PubMed

9. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. (Full text)

Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients.In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (...) had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI

2014 NEJM PubMed

10. Losartan and enalapril are comparable in reducing proteinuria in children (Full text)

Losartan and enalapril are comparable in reducing proteinuria in children Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers delay progression of chronic kidney disease and have antiproteinuric effects beyond their effects on blood pressure. They are routinely used in adults; however, their efficacy and safety in children, in whom the causes of chronic kidney disease are significantly different relative to adults, is uncertain. Here we assessed an open-label (...) extension of a previous 3-month blinded trial, in which the efficacy and tolerability of losartan was compared to placebo or amlodipine in 306 normotensive and hypertensive children with proteinuria. In this study, 268 children were re-randomized to losartan or enalapril and followed until 100 patients completed 3 years of follow-up for proteinuria and renal function. The least squares percent mean reduction from baseline in the urinary protein/creatinine ratio was 30.01% for losartan and 40.45

2013 EvidenceUpdates PubMed

11. Epaned (enalapril) for Oral Solution

Epaned (enalapril) for Oral Solution Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - EPANED (enalapril) for Oral Solution Company: Silvergate Pharmaceuticals, Inc. Application No.: 204308 Approval Date: 8/13/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2013 FDA - Drug Approval Package

12. Enalapril in Infants With Single Ventricle: Results of a Multicenter Randomized Trial (Full text)

Enalapril in Infants With Single Ventricle: Results of a Multicenter Randomized Trial Angiotensin-converting enzyme inhibitor therapy improves clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology have poor growth and are at risk for abnormalities in ventricular systolic and diastolic function. The ability of angiotensin-converting enzyme inhibitor therapy to preserve ventricular function and improve somatic growth and outcomes (...) in these infants is unknown.The Pediatric Heart Network conducted a double-blind trial involving 230 infants with single-ventricle physiology randomized to receive enalapril (target dose 0.4 mg . kg(-1) . d(-1)) or placebo who were followed up until 14 months of age. The primary end point was weight-for-age z score at 14 months. The primary analysis was intention to treat. A total of 185 infants completed the study. There were 24 and 21 withdrawals or deaths in the enalapril and placebo groups, respectively (P

2010 EvidenceUpdates PubMed

13. Renal and retinal effects of enalapril and losartan in type 1 diabetes. (Full text)

Renal and retinal effects of enalapril and losartan in type 1 diabetes. Nephropathy and retinopathy remain important complications of type 1 diabetes. It is unclear whether their progression is slowed by early administration of drugs that block the renin-angiotensin system.We conducted a multicenter, controlled trial involving 285 normotensive patients with type 1 diabetes and normoalbuminuria and who were randomly assigned to receive losartan (100 mg daily), enalapril (20 mg daily), or placebo (...) the 5-year period did not differ significantly between the placebo group (0.016 units) and the enalapril group (0.005, P=0.38) or the losartan group (0.026, P=0.26), nor were there significant treatment benefits for other biopsy-assessed renal structural variables. The 5-year cumulative incidence of microalbuminuria was 6% in the placebo group; the incidence was higher with losartan (17%, P=0.01 by the log-rank test) but not with enalapril (4%, P=0.96 by the log-rank test). As compared with placebo

2009 NEJM PubMed

14. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe: the HEALTH model (Full text)

Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe: the HEALTH model Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe: the HEALTH model Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe: the HEALTH model Schwander B, Gradl B, Zollner Y, Lindgren P, Diener (...) HC, Luders S, Schrader J, Antonanzas Villar F, Greiner W, Jonsson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of eprosartan and enalapril in the primary prevention

2009 NHS Economic Evaluation Database. PubMed

15. Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure

Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failureCommentary | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failureCommentary Article Text Causation Enalapril and captopril increased

2008 Evidence-Based Nursing

16. Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril

Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril Wagner M, Rindress D, Desjardins B, Meilleur M C, Ducharme A, Tardif J C Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the impact of enalapril on the incidence of atrial fibrillation (AF) in patients with heart failure (HF). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population

2005 NHS Economic Evaluation Database.

17. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. (PubMed)

Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. In the studies of left ventricular dysfunction (SOLVD), enalapril reduced mortality in patients with symptomatic but not asymptomatic left ventricular systolic dysfunction during the trial. We did a 12-year follow-up of SOLVD to establish if the mortality reduction with enalapril among patients with heart failure was sustained, and whether a subsequent reduction (...) . In the prevention trial, 50.9% (1074/2111) of the enalapril group had died compared with 56.4% (1195/2117) of the placebo group (generalised Wilcoxon p=0.001). In the treatment trial, 79.8% (1025/1285) of the enalapril group had died compared with 80.8% (1038/1284) of the placebo group (generalised Wilcoxon p=0.01). The reductions in cardiac deaths were significant and similar in both trials. When data for the prevention and treatment trials were combined, the hazard ratio for death was 0.90 for the enalapril

2003 Lancet

18. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. (PubMed)

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. It has recently been reported that the use of calcium-channel blockers for hypertension may be associated with an increased risk of cardiovascular complications. Because this issue remains controversial, we studied the incidence of such complications in patients with non-insulin-dependent diabetes mellitus and hypertension who were randomly assigned (...) to treatment with either the calcium-channel blocker nisoldipine or the angiotensin-converting-enzyme inhibitor enalapril as part of a larger study.The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial is a prospective, randomized, blinded trial comparing the effects of moderate control of blood pressure (target diastolic pressure, 80 to 89 mm Hg) with those of intensive control of blood pressure (diastolic pressure, 75 mm Hg) on the incidence and progression of complications of diabetes

1998 NEJM

19. The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction

The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction Cook J R, Glick H A, Gerth W, Kinosian B, Kostis J B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of enalapril for the treatment of hypertensive patients with left ventricular dysfunction. Type of intervention Secondary prevention and treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The study population comprised patients who had

1998 NHS Economic Evaluation Database.

20. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. (Full text)

Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. To compare the effectiveness and tolerability of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in patients with mild to moderate hypertension.Randomised multicentre trial over 48 weeks with double blind comparison of treatments.48 centres in four countries.868 patients with essential (...) hypertension (diastolic blood pressure 95-120 mm Hg)Initial treatment (step 1) consisted of 12.5 mg hydrochlorothiazide (n = 215), 25 mg atenolol (n = 215), 10 mg nitrendipine (n = 218), or 5 mg enalapril (n = 220) once daily. If diastolic blood pressure was not reduced to < 90 mm Hg within four weeks, doses were increased to 25 mg, 50 mg, 20 mg, 10 mg, respectively, once daily (step 2) and after two more weeks to twice daily (step 3). The eight week titration phase was followed by an additional 40 weeks

1997 BMJ PubMed